Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone Acetate, Prednisone, and Apalutamide in Hormone-Naive Metastatic Prostate Cancer
NCT03821792Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2019
- Primary completion
- Oct 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of Abiraterone Acetate Tablets (I), apalutamide in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2019; status: active, not recruiting.
02
Drugs
Abiraterone Acetate Tablets (I)apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03821792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821792.